Abstracts tagged "Disease Activity"

Abstract Number: 1903 • 2016 ACR/ARHP Annual Meeting
Determining Disease Course in Localized Scleroderma: A Prospective Cohort Study
Jack O'Brien¹ and Heidi Jacobe², ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA, Dallas, TX, ²Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Localized scleroderma (LS) is characterized by skin sclerosis, producing devastating impairment in those affected. It was previously thought to “burn out” within 5 years,…
Abstract Number: 2470 • 2016 ACR/ARHP Annual Meeting
Treat to Target: Theoretical Agreement Vs Daily Applicability
Leonardo Romeiro¹, Dalton Torigoe², Claiton Brenol³, Roberto Ranza⁴, Lícia M. H. Mota⁵, Manoel Bertolo⁶, Max Freitas⁷, José Tupinambá⁸, Ivanio Pereira⁹, Lucila Fronza¹⁰ and Ieda Maria Magalhães Laurindo¹¹, ¹Rheumatology, UNESA, Rio de Janeiro, Rio de Janeiro, Brazil, ²Faculdade de Medicina da Santa Casa de Misericordia, São Paulo, Brazil, ³Rua Cabral, 764 – Apto 302, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁴Reumatologia, Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ⁵Hospital Universitário de Brasília - UnB, Brasília, Brazil, ⁶INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil, ⁷Pathology, Federal University of Ceara, Fortaleza, Brazil, ⁸Universidade Federal do Piaui, Teresina, Brazil, ⁹Rheumatology, Universidade do Sul de Santa Catarina, Florianopolis, Brazil, ¹⁰CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, Brazil, ¹¹Internal Medicine - Rheumatology, Faculdade de Medicina da Universidade Nove de Julho, São Paulo, Brazil
Background/Purpose: Treat to target (T2T) strategy has been widely recognized as effective and leading to better outcomes. There have been no questions regarding its theoretical…
Abstract Number: 2713 • 2016 ACR/ARHP Annual Meeting
Differentially Expressed Microrna As Candidate Biomarker for Disease Activity in Ankylosing Spondylitis
Marina N. Magrey¹, Abdul Haseeb² and Tariq M Haqqi², ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH
Differentially Expressed MicroRNA as candidate Biomarker for Disease Activity in Ankylosing Spondylitis Background/Purpose: MicroRNAs (miRNAs) have evolved as a novel class of biomarkers We proposed…
Abstract Number: 2860 • 2016 ACR/ARHP Annual Meeting
Exercise Significantly Improves Cardiorespiratory Fitness and Reduces Disease-Related Fatigue without Adverse Effects on Disease Activity in Systemic Lupus Erythematosus: a Systematic Review with Meta-Analysis
Tom O'Dwyer¹, Laura Durcan² and Fiona Wilson³, ¹Physiotherapy, Trinity College Dublin, Dublin, Ireland, ²University of Washington, Seattle, WA, ³Physiotherapy, Trinity College, Dublin, Ireland
Background/Purpose: Systemic lupus erythematous (SLE) associates with accelerated mortality, frequently attributable to cardiovascular (CV) causes, which is not fully explained by traditional CV risk factors.…
Abstract Number: 3196 • 2016 ACR/ARHP Annual Meeting
A Natural Language Processing System Can Capture Rheumatoid Arthritis Disease Activity Measures in US Veterans Across Multiple Sites
Grant W. Cannon¹, Shobhit Mehortra², Brett South², Ted R Mikuls³, Andreas M. Reimold⁴ and Brian C Sauer², ¹Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX
Background/Purpose: The retrieval of rheumatoid arthritis (RA) disease activity measures recorded in an electronic medical record through natural language processing (NLP) would significantly aid…
Abstract Number: 279 • 2016 ACR/ARHP Annual Meeting
Increased Heat Shock Protein 90 in Muscle Tissue and Plasma in Idiopathic Inflammatory Myopathies Correlates with Disease Activity and Skeletal Muscle Involvement
Hana Storkanova¹, Olga Krystufkova¹, Martin Klein², Herman F Mann¹, Lucia Vernerova¹, Maja Spiritovic^1,3, Josef Zámecník⁴, Karel Pavelka², Ladislav Senolt¹, Jiří Vencovský¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic
Background/Purpose: Heat shock proteins (Hsps) are chaperones playing important roles in skeletal muscle physiology, adaptation to exercise or stress, and activation of inflammatory cells. The…
Abstract Number: 559 • 2016 ACR/ARHP Annual Meeting
Comparison of Multi-Dimensional Health Assessment Questionnaire (MD-HAQ)-Based and Patient-Reported Outcomes Measurement Information System (PROMIS) 29-Based Routine Assessment of Patient Index 3 (RAPID3) for Assessing Rheumatoid Arthritis Disease Activity
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio² and Larry W. Moreland¹, ¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, School of Public Health, Pittsburgh, PA
Background/Purpose: Patient-reported outcomes measurement information system (PROMIS) 29 is recommended by the National Institute of Health (NIH) consensus panel as the preferred battery of…
Abstract Number: 941 • 2016 ACR/ARHP Annual Meeting
An International, Multi-Specialty Validation Study of the IgG4-Related Disease Responder Index
Zachary Wallace¹, Arezou Khosroshahi², Mollie Carruthers³, Campochiaro Corrado⁴, Hyon K. Choi⁵, Emma Culver⁶, Frank Cortazar⁷, Mikael Ebbo⁸, Ana Fernandes⁹, Luca Frulloni¹⁰, Omer Karadag¹¹, Shigeyuki Kawa¹², Mitsuhiro Kawano¹³, MH Kim¹⁴, Marco Lanzillotta¹⁵, Shoko Matsui¹⁶, Cory Perugino¹⁷, Kazuichi Okazaki¹⁸, Philip Hart¹⁹, Jay H. Ryu²⁰, Takako Saeki²¹, Nicolas Schleinitz²², Paula Tanasa²³, Hisanori Umehara²⁴, George Webster²⁵, Wen Zhang²⁶ and John H. Stone²⁷, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴San Raffaele Scientific Institute, Milan, Italy, ⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁶Translational Gastroenterology Unit and NDM Oxford University, Translational Gastroenterology Unit and NDM Oxford University, John Radcliffe Hospital/Oxford University, Oxford, United Kingdom, ⁷Department of Nephrology, Massachusetts General Hospital, Boston, MA, ⁸Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ⁹Rheumatology Unit, Massachusetts General Hospital, Boston, MA, ¹⁰Gastroenterology, University of Verona, Verona, Italy, ¹¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹²Center for Health, Safety and Environmental Management, Shinshu University, Matsumoto, Japan, ¹³Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ¹⁴University of Ulsan College of Medicine, Seoul, Korea, The Republic of, ¹⁵Vita-Salute San Raffaele University, Milan, Italy, ¹⁶University of Toyama, Toyama, Japan, ¹⁷Rheumatology, Massachusetts General Hospital, Boston, MA, ¹⁸Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan, ¹⁹Ohio State University Wexner Medical Center, Columbus, OH, ²⁰Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ²¹Nagaoka Red Cross Hospital, Niigata, Japan, ²²La Timone University Hospital, Marseille, France, ²³Rheumatology, Emory University, Atlanta, GA, ²⁴Kyoto University, Kyoto, Japan, ²⁵University College Hospital, London, United Kingdom, ²⁶Rheuamtology, Peking Union Medical College Hospital, Beijing, China, ²⁷Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition responsible for fibro-inflammatory lesions that can affect nearly any organ and lead to irreversible damage. To evaluate…
Abstract Number: 1376 • 2016 ACR/ARHP Annual Meeting
In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity
Kristin Schjander Berntsen¹, Berit Flatø^1,2, Ivar Sjaastad^2,3 and Helga Sanner^1,4, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ³Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway, Oslo, Norway, ⁴Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway
Background/Purpose: All previous studies of disease outcome in juvenile dermatomyositis (JDM) patients have been based on retrospective data or cross sectional examination. We aimed to…
Abstract Number: 1592 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in RA Patients with an Inadequate Response to Subcutaneous Tocilizumab Every Other Week
Atsushi Ogata¹, Nobuhiro Takagi², Hiroko Miwa³ and the MRA231JP study group, ¹Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine and NTT West Osaka Hospital, Osaka, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, ³Chugai Pharmaceutical Co. Ltd, Tokyo, Japan
Background/Purpose: The non-inferiority of subcutaneous tocilizumab (TCZ-SC) monotherapy every 2 weeks (q2w) to intravenous TCZ monotherapy every 4 weeks was demonstrated in Japanese patients with…
Abstract Number: 1919 • 2016 ACR/ARHP Annual Meeting
Analysis of T Cell Repertoire Diversity of CD4+ Memory and NaïVe T Cells By Next Generation Sequencing and Its Association with Rheumatoid Arthritis Disease Parameters
Keiichi Sakurai¹, Hirofumi Shoda¹, Kazuyoshi Ishigaki², Yumi Tsuchida¹, Yasuo Nagafuchi¹, Shuji Sumitomo¹, Akari Suzuki², Keishi Fujio¹ and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by peripheral polyarthritis. The importance of CD4+ T cell in the pathophysiology of RA is well-known…
Abstract Number: 2485 • 2016 ACR/ARHP Annual Meeting
Correlates of Successful Flare Management: The Role of Clinician-Driven Treatment, Home-Based Strategies, and Medication Change
Taysir G. Mahmoud¹, M Frits², Christine Iannaccone³, Vivian P. Bykerk⁴, Clifton Bingham III⁵, Michael Weinblatt³ and N A Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Flares are a common experience in RA, often associated with worse clinical outcomes such as cardiovascular disease, lower functional status, and radiographic progression. …
Abstract Number: 2719 • 2016 ACR/ARHP Annual Meeting
Discriminating Value of Calprotectin in Disease Activity and Progression of Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
Jinxian Huang¹, Zhihua Yin², Guoxiang Song³, Shengjin Cui⁴, Jinzhao Jiang⁴ and Lijun Zhang⁴, ¹Rheumatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China, ²Rheumatology, The Fourth People’s Hospital of Shenzhen, Shenzhen, China, ³The Third People’s Hospital of Shenzhen, Shenzhen, China, ⁴The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
Background/Purpose: Due to the limitation of early diagnosis of ankylosing spondylitis (AS), updated criteria in recent years introduced the concept of axial spondyloarthritis (axSpA) and…
Abstract Number: 2862 • 2016 ACR/ARHP Annual Meeting
Whole Blood Phenotyping and Innate and Adaptive Stimulation Reveal Unique Differences in Granulocytes and Innate Pathways of African American SLE Patients with Variable Disease Activity
Samantha Slight-Webb¹, Krista M. Bean¹, Joseph Kheir¹, Bolanle Adebayo¹, Holden T. Maecker², Paul J. Utz³, Judith A. James⁴ and Joel M. Guthridge⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by periods of heightened disease activity. Disease flares significantly affect quality of life and…
Abstract Number: 3228 • 2016 ACR/ARHP Annual Meeting
Specific T Cell and B Cell Distributions Characterize Subgroups of Patients with Primary Sjögren’s Syndrome and Are Associated with Disease Activity and Pro-Inflammatory Cytokine Expression
Lucas Le Lann¹, Quentin Simon¹, Christophe Jamin¹, Maria Orietta Borghi², Lorenzo Beretta³, Ricard Cervera⁴, Alain Saraux⁵, Divi Cornec¹, Rik Lories⁶, Carlo Chizzolini⁷, Marta E. Alarcon Riquelme⁸, Jacques-Olivier Pers¹ and on behalf of the PRECISESADS Consortium, ¹INSERM ERI29, EA2216, Université de Brest, Labex IGO, CHRU Morvan, Brest, France, ²University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ³Rheumatology, Milan, Italy, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven and University Hospitals Leuven., Leuven, Belgium, ⁷University hospital of Geneva, Geneva, Switzerland, ⁸Centro de Genomica e Investigación Oncológica, Pfizer-University of Granada-Junta de Andalucía, Granada, Spain
Background/Purpose : The goal of the IMI PRECISESADS project is to reclassify individuals affected by systemic autoimmune diseases (SADs) into clusters of molecular, instead of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].